A letter of recommendation from Dr T.D. Meakin B.Sc. M.D. FRNZCGP May 11, 2015 10:31
Dear Ibsacol Customer,
I was involved in further clinical trials during May 2002. These investigations involved the active ingredient of IBSACOL and were conducted at the Liggins Research Institute in Auckland New Zealand. This trial required the monitoring of blood and the recording of adverse reaction by patients. No negative effects were recorded on the blood profiles and the patient involved reported no adverse side effects.
I have been impressed with the results of these studies and conclude that IBSACOL appears to be a safe and well-tolerated therapy.
Dr. T.D. Meakin B.Sc. M.D. FRNZCGP
Auckland, New Zealand